SCHEMBL24257724

SCHEMBL24257724

CCOC(=O)CNC(=O)c1ncc(-c2cnn(-c3ccc(F)cc3)c2)c(C)c1OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 1/20 0.39
ALDH1A1 P00352 2/20 0.39
GRM4 Q14833 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
PPID Q08752 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
MAPT P10636 2/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 2/20 0.36
KDM4E B2RXH2 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257745 0.94 GRM4 (0.42) RIPK2ALDH1A1GRM4NPC1RAB9A
SCHEMBL26259966 0.86 ALDH1A1 (0.39) RIPK2ALDH1A1GRM4PPIDKMT2A
SCHEMBL24257566 0.86 GRM4 (0.44) RIPK2GRM4NPC1RAB9AKMT2A
SCHEMBL24257767 0.85 NPC1 (0.41) RIPK2ALDH1A1GRM4NPC1RAB9A
SCHEMBL24257538 0.84 KMT2A (0.39) ALDH1A1PPIDKMT2AMEN1MAPT
SCHEMBL30452640 0.82 EGLN1 (0.46) PPIDKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL24257548 0.82 EGLN1 (0.46) PPIDKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL24257785 0.82 KMT2A (0.42) ALDH1A1PPIDKMT2AMEN1MAPT
SCHEMBL24257699 0.81 HPGD (0.44) ALDH1A1GRM4NPC1RAB9APPID
SCHEMBL24257514 0.80 ALDH1A1 (0.48) ALDH1A1PPIDKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 RIPK2 113/4885ALDH1A1 1362/4885GRM4 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.